中国医药科学2016，Vol.6Issue(14)：18-23,6.
VAD、改良M2和MP方案联合沙利度胺治疗多发性骨髓瘤的疗效观察及对比研究
Curative effect observation and contrastive study of VAD, improved M2 and MP program combined with thalidomide in treatment of multiple myeloma
宋敏 1王建宁 1孟庆齐 1侯艳秋 1张柳波 1付行财 1包红雨 1蒋苏豫1
作者信息
- 1. 南京医科大学第二附属医院血液科，江苏南京 210011
- 折叠
摘要
Abstract
Objective To evaluate the curative effect of VAD,improved M2 and MP program combined with thalidomide in treatment of multiple myeloma (MM).MethodsAccording to the patient’s condition,economic situation and individual will,39 cases of patents with MM were divided into three groups.26 patients were treated with VAD,which included 20 cases with newly diagnosed MM,21 patients were treated with improved M2 and MP program (Chemotherapy regimens including melphalan),which included 13 cases with newly diagnosed newly diagnosed MM.14 patients were treated with improved M2,which included 4 cases with newly diagnosed MM and 10 cases with recurrently diagnosed MM.15 patients were treated with MP,which included 10 cases with newly diagnosed MM and 5 cases with recurrently diagnosed MM.8 patients were treated with MP and M2 program repetition.8 patients were treated with successively VAD and improved M2 or MP program repetition.Results The total effective rate of VAD group and Melphalan (M) group (OR)(≥PR) respectively were 80% and 76.9% (P>0.05).The total effective rate of patients with newly diagnosed MM of VAD group and Melphalan (M) group (OR)(≥VGPR) respectively were 60.0% and 46.2% (P>0.05).The total effective rate of patients with newly and recurrently diagnosed MM of VAD group and Melphalan (M) group (OR)(≥PR) respectively were 76.9% (26 cases in VAD group) and 57.1% (21 cases in M group) (P>0.05).The total effective rate of patients with newly diagnosed MM of VAD group and Melphalan (M) group (OR)(≥VGPR) respectively were 53.8% and 42.9% (P>0.05).There are 4 cases of VGCR or more curative effect among the 10 cases of newly diagnosed MP.There are 3cases of VGCR or more curative effect among the 4 cases of newly diagnosed improved M2.The effect of 3 cases of patients with newly diagnosed VAD was poor.After switching to M2 program, it was up to VGPR efficacy.Overall survival (OS) time of VAD group and M group respectively were 39 months and 25 months for patients with new diagnosis (P>0.05),39 months and 50 months for patients with new and recurrent diagnosis (P>0.05).Progression free survival (PFS) time of VAD group and M group respectively were 31 months and 18 months for patients with new diagnosis (P>0.05),29 months and 31 months for patients with new and recurrent diagnosis (P>0.05).Conclusion VAD,improved M2 and MP program combined with thalidomide chemotherapy is an economical and effective solution to individually doctor elderly patients with MM.关键词
多发性骨髓瘤/VAD/M2/MPKey words
Multiple myeloma/VAD/M2/MP分类
医药卫生引用本文复制引用
宋敏,王建宁,孟庆齐,侯艳秋,张柳波,付行财,包红雨,蒋苏豫..VAD、改良M2和MP方案联合沙利度胺治疗多发性骨髓瘤的疗效观察及对比研究[J].中国医药科学,2016,6(14):18-23,6.
